Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial ESTO2/FinnProstata XV
Starting year
2024
Granted funding
Teemu Murtola 
300 000 €
Funder
Cancer Foundation Finland sr.
Other information
Funding decision number
A2875
Fields of science
Cancers
Identified topics
cancer